INTRODUCTION
============

Intracellular calcium ions (Ca^2+^) regulate neuronal signaling in the central nervous system ([@B13]; [@B10]). Neuronal Ca^2+^ signals are detected by a family of neuronal calcium sensor (NCS) proteins ([@B8], [@B5]; [@B17]; [@B21]; [@B20]; [@B134]) that contain EF-hand motifs ([@B87]; [@B60]; [@B61]) as well as by a family of C~2~-domain containing proteins (synaptotagmin and protein kinase C isoforms; [@B89]; [@B29]). At least sixteen different NCS proteins are known ([@B133]; [@B19]) and are conserved from yeast to humans (**Figure [1](#F1){ref-type="fig"}**). Recoverin ([@B39]) and guanylyl cyclase activating proteins 1 and 2 (GCAP1 and GCAP2; [@B36]; [@B98]) are expressed in the retina, where they regulate phototransduction in photoreceptor cells ([@B96]; [@B1]; [@B121]; [@B5]). NCS proteins are also expressed in the brain such as neurocalcin ([@B53]), frequenin (NCS-1; [@B108]; [@B85]), visinin-like proteins (VILIPs; [@B12]; [@B18]), K^+^ channel interacting proteins (KChIPs; [@B9]), calsenilin/DREAM ([@B23]; [@B25]), and hippocalcin ([@B67], [@B68]; [@B129]).

![**Amino acid sequence alignment of selected NCS proteins (sequence numbering is for *S.* pombe NCS-1).** Secondary structure elements (helices and strands), EF-hand motifs (EF1 green, EF2 red, EF3 cyan, and EF4 yellow), and residues that interact with the myristoyl group (highlighted magenta) are indicated. Swiss Protein Database accession numbers are Q09711 (*S. pombe* NCS-1), Q06389 (*S. cerevisiae* Frq1), P21457 (bovine recoverin), and P43080 (human GCAP1).](fnmol-07-00019-g001){#F1}

Recoverin also called [S]{.smallcaps}-modulin ([@B39]; [@B65]), the first NCS protein to be discovered, controls the lifetime of photo-excited rhodopsin ([@B64]; [@B41]; [@B81]) by regulating rhodopsin kinase ([@B24]; [@B26]; [@B66]; [@B70]). Recoverin decreases the lifetime of rhodopsin at low Ca^2+^ levels to control visual recovery and promote photoreceptor adaptation to background light. More recent evidence indicates that recoverin can also modulate the decay of the light-activated phsophodiesterase activity. Such modulation may help accelerate visual recovery in the presence of background light ([@B27]). Recoverin is also located in the rod inner segment ([@B124]) and is associated with cancer-associated retinopathy ([@B107]; [@B125]).

Guanylyl cyclase activating proteins 1 and 2 are also expressed in photoreceptor cells where they activate retinal guanylyl cyclase at low cytosolic Ca^2+^ levels upon light activation ([@B36]; [@B98], [@B97]). The EF-hand motifs in GCAPs can bind both Mg^2+^ and Ca^2+^ ([@B100], [@B101]). Mg^2+^ binding stabilizes a structural form of GCAPs that activates cyclase activity ([@B101]; [@B77]), whereas Ca^2+^-bound GCAPs inhibit the cyclase ([@B35]; [@B32]). GCAPs are important for regulating the recovery phase of visual excitation and particular mutants are linked to various forms of retinal degeneration ([@B115]; [@B117]; [@B11]; [@B15]; [@B62]).

Neuronal calcium sensor proteins (frequenin or NCS-1) are expressed in other tissues beside the brain ([@B63]) and in lower organisms including flies ([@B108]), worms ([@B45]), and yeast (Frq1; [@B52]; [@B57]; [@B51]). Yeast NCS homologs (called Frq1) activate a phosphatidyl inositol 4-OH kinase isoform (Pik1; [@B52]; [@B63]; [@B122], [@B123]) required for vesicle trafficking and secretion ([@B50]; [@B131]). Mammalian NCS-1 interacts with voltage-gated Ca^2+^ and K^+^ channels ([@B132]; [@B88]) and activates inositol trisphosphate receptors ([@B14]).

NCS proteins typically contain about 200 amino acid residues in chain length with four EF-hand motifs, a first EF-hand that does not bind Ca^2+^, and a myristoylation consensus sequence at the N-terminus. NCS proteins have similar sequences, ranging from 35 to 60% identity (**Figure [1](#F1){ref-type="fig"}**). EF-hand residues are the most highly conserved, particularly in the Ca^2+^ binding loops. The fourth EF-hand sequence is variable, and Ca^2+^ is able to bind to EF4 in frequenin ([@B30]; [@B3]) and GCAPs ([@B102]; [@B120]) but Ca^2+^ does not bind to EF4 in recoverin ([@B6]) and VILIPs ([@B30]; [@B76]). Ca^2+^-binding to EF4 in GCAP1 controls whether GCAP1 can activate or inhibit guanylyl cyclase ([@B102]). The residues near the C-terminus and linker between EF3 and EF4 are non-conserved, suggesting that these regions may play a role in target specificity for recoverin but not for GCAPs.

Retinal recoverin and most other NCS proteins are myristoylated at the amino terminus ([@B34]; [@B68]; [@B74]). Recoverin and GCAPs contain a saturated myristoyl (14:0) or related fatty acyl group (12:0, 14:1, 14:2), because [N]{.smallcaps}-myristoyl transferase ([@B48]) can efficiently utilize C12 and/or C14 acetyl-CoA as fatty acyl donors in the retina. In tissues other than the retina, myristoylation is the predominant modification. Myristoylated recoverin binds to cell membranes only at high Ca^2+^ levels ([@B140]; [@B33]), whereas unmyristoylated recoverin does not bind to membranes. Likewise, bovine neurocalcin ([@B74]) and hippocalcin ([@B68]) both are myristoylated and exhibit Ca^2+^-induced localization at the plasma membrane in response to neuronal stimulation. Ca^2+^-induced membrane targeting by NCS proteins has been termed, Ca^2+^-myristoyl switch. The attached fatty acyl group is buried inside the protein structure of Ca^2+^-free recoverin ([@B126]). Ca^2+^ binding to recoverin causes extrusion of the fatty acid, enabling it to interact with lipid bilayer membranes. Recoverin's Ca^2+^-myristoyl switch may control its light-induced movement into the rod inner segment ([@B124]). GCAP proteins are also myristoylated ([@B98]; [@B43]; [@B94]). However, unlike recoverin, GCAPs do not possess a functional Ca^2+^-myristoyl switch ([@B94]; [@B58]). Instead the N-terminal myristoyl group remains sequestered inside GCAP1 in both Ca^2+^-free and Ca^2+^-bound states ([@B55]; [@B77]). Indeed, the crystal structure of Ca^2+^-bound GCAP1 shows the myristoyl group surrounded by the protein ([@B120]), and a recent nuclear magnetic resonance (NMR) structural analysis reveals that the activator state of GCAP1 has an overall structure similar to that of Ca^2+^-bound inhibitory state in which the N-terminal myristoyl group is buried in both the Ca^2+^-free and Ca^2+^-bound states ([@B78]).

Atomic-resolution structures are known for myristoylated forms of recoverin ([@B4]), GCAP1 ([@B120]), and NCS-1 ([@B79]) that each fold differently around the attached myristoyl group (**Figure [2](#F2){ref-type="fig"}**). For NCS-1, the attached myristoyl group is located in a protein crevice formed by helices from EF3 and EF4 near the C-terminus (**Figure [2A](#F2){ref-type="fig"}**). The covalently attached fatty acyl group in NCS-1 protrudes in a parallel fashion between four helices from EF3 and EF4 (**Figure [2B](#F2){ref-type="fig"}**). The C-terminal location of the myristoyl binding site in NCS-1 is quite different from that of recoverin in which the myristate is positioned inside a cavity near the N-terminus (**Figure [2C](#F2){ref-type="fig"}**). The attached fatty acyl chain in recoverin is wedged between the helices of EF1 and EF2 in a perpendicular fashion (**Figure [2D](#F2){ref-type="fig"}**), which contrasts with the parallel arrangement of the fatty acyl chain in NCS-1 (**Figure [2B](#F2){ref-type="fig"}**). For GCAP1, the myristoyl group is sequestered in a cavity formed by the N-terminal domain with participation of a C-terminal helix (**Figure [2E](#F2){ref-type="fig"}**). The myristoyl group in GCAP1 bridges the N-terminal and C-terminal ends of the protein by contacting helices at each end (**Figure [2F](#F2){ref-type="fig"}**). In short, the protein structural environment around the myristoyl group is quite different in recoverin, GCAP1 and NCS-1 (**Figure [2](#F2){ref-type="fig"}**). This suggests that each NCS protein folds differently around the N-terminal myristoyl group by contacting non-conserved patches of hydrophobic residues that are unique to each NCS protein. However, myristoylation of GCAP2 is not essential for its ability to activate its target (retinal guanylyl cyclase), because unmyristoylated GCAP2 can activate cyclase activity nearly as well as myristoylated GCAP2 ([@B94]).

![**Main chain structures of Ca^2+^-free myrisoylated NCS-1 (PDB ID: 212e) (A), recoverin (PDB ID: 1iku) (C), and GCAP1 (PDB ID: 2r2i) (E)**. Close-up views of the myristate binding pocket in NCS-1 **(B)**, recoverin **(D)** and GCAP1 **(F)**. EF-hands and myristoyl group (magenta) are colored as defined in **Figure [1](#F1){ref-type="fig"}**. Adapted from and originally published by [@B79].](fnmol-07-00019-g002){#F2}

In this review, we discuss recent structures of GCAP1 in both Ca^2+^-free activator and Ca^2+^-bound inhibitor states to understand structural determinants that control Ca^2+^-dependent activation of retinal guanylyl cyclases.

Ca^2+^-DEPENDENT ACTIVATION OF RETINAL GUANYLYL CYCLASE
=======================================================

GUANYLYL CYCLASE ACTIVATION AND PHOTORECEPTOR RECOVERY
------------------------------------------------------

In vertebrate rods and cones, photon absorption by rhodopsin or cone visual pigments triggers a phototransduction cascade that hydrolyzes cGMP, resulting in the closure of cGMP-gated cation channels on the plasma membrane that causes membrane hyperpolarization \[see reviews ([@B109], [@B110])\]. To reset the resting dark-state of retinal rods (known as visual recovery), cGMP levels are replenished very quickly ([@B22]) by retina-specific guanylyl cyclases (RetGCs), a membrane enzyme present in rod and cone outer segments ([@B36]; [@B80]). RetGC is a Ca^2+^-regulated enzyme ([@B69]; [@B72]) whose activity is controlled by intracellular domains ([@B75]; [@B40]) that interact with soluble EF-hand Ca^2+^ sensor proteins, called guanylyl cyclase activating proteins (GCAPs: GCAP1 and GCAP2; [@B36], [@B38]; [@B47], [@B46]; [@B71]).

Light-induced channel closure in photoreceptor cells causes a decrease in the cytosolic free Ca^2+^ concentration ([@B49]), in mammals from 250 nM in the dark to 25 nM in the light ([@B138]). The catalytic activity of RetGC in the dark is negatively controlled by Ca^2+^-bound GCAPs ([@B35]; [@B32]; [@B22]), whereas the release of Ca^2+^ from GCAPs at low Ca^2+^ levels in light-activated photoreceptors causes activation of RetGC ([@B36], [@B38]; [@B47], [@B46]; [@B35]; [@B86]). Light stimulation of the rod cell causes a more than 10-fold increase in cGMP production due to the activation of RetGC by GCAPs ([@B54]; [@B22]) and is a critical step for controlling the recovery rate of a single-photon response ([@B110]; [@B22]) as well as the cone response to stronger light stimuli ([@B112]). In mouse rods, GCAPs have been demonstrated to have different Ca^2+^ sensitivities ([@B32]; [@B59]) and therefore contribute to the recovery by activating guanylyl cyclase at different steps of excitation and recovery, thus imparting proper recovery kinetics to the rod response ([@B86]; [@B82], [@B83]).

Mg^2+^ AND Ca^2+^ BINDING TO GCAPs RECIPROCALLY CONTROL CYCLASE ACTIVATION
--------------------------------------------------------------------------

Guanylyl cyclase activating proteins activate RetGC at low Ca^2+^ levels (less than 50 nM) and only in the presence of physiological Mg^2+^ levels ([@B100], [@B101], [@B102]; [@B37]). This Mg^2+^ requirement for RetGC activation by GCAPs initially suggested that Mg^2+^ binding to GCAPs might be important for their activation of RetGC. Indeed, Mg^2+^ was shown to bind directly to at least two of the EF-hands in GCAP1 ([@B77]), and NMR studies showed that Mg^2+^ binding to GCAP1 at EF2 and EF3 was needed to stabilize the overall tertiary fold of the protein ([@B77]). By contrast, the Ca^2+^-free/Mg^2+^-free GCAP1 (apo-state) forms a molten globule-like structure, that contains regular secondary structure ([@B31]) but does not form a stable tertiary fold ([@B100]; [@B77]). The flexible and unstructured molten-globule apo-protein could explain in part why GCAPs do not activate RetGC in the absence of Mg^2+^ ([@B37]). Thus, Mg^2+^ binding to GCAP1 stablizes its protein structure in order to bind and activate RetGC ([@B36]; [@B100]), whereas Ca^2+^ binding to GCAP1 stabilizes a distinct structure important for the inhibition of RetGC ([@B32]).

The four EF-hands in the GCAPs have quite distinct divalent metal binding properties that control whether GCAPs can activate or inhibit RetGC. The first EF-hand (EF1) does not bind to either Ca^2+^ or Mg^2+^ because the residue at the 3-position in the EF-hand binding loop (Cys29 in GCAP1, see **Figure [1](#F1){ref-type="fig"}**) is not suitable for ligating either Ca^2+^ or Mg^2+^. Ca^2+^ binds to GCAP1 at the other three EF-hands (EF2, EF3, and EF4) in an independent fashion ([@B77]) in contrast to the cooperative binding of two Ca^2+^ to recoverin ([@B6]). The apparent dissociation constant for Ca^2+^ binding to GCAPs is in the submicromolar range ([@B77]; [@B37]), whereas Mg^2+^ binds with \~1000-fold lower affinity ([@B44]) in the sub-millimolar range ([@B100], [@B102]; [@B77]). These binding affinities imply that three Ca^2+^ bind per mole of GCAP1 in dark-adapted rod cells, which have relatively high cytosolic Ca^2+^ levels \[Ca^2+^\]~free~ = 250--500 nM \[([@B138]; [@B84]) and \[Mg^2+^\] \~1 mM ([@B28])\]. Light-activation of the rod cell causes a dramatic lowering of the cytosolic Ca^2+^ level \[Ca^2+^\]~free~ = 5--50 nM ([@B49]; [@B113]; [@B138]) while the Mg^2+^ level remains fixed at \[Mg^2+^\]~free~ \~1 mM ([@B28]). Therefore in light-adapted rods, GCAPs do not bind Ca^2+^ but instead bind to at least two Mg^2+^. Thus, Ca^2+^-free/Mg^2+^-bound GCAPs activate RetGC in light exposed rods ([@B36], [@B38]; [@B46]), whereas Ca^2+^-bound GCAPs (with Ca^2+^ bound at EF2, EF3, and EF4) inhibit RetGC in dark-adapted rods ([@B35]; [@B32]).

CONSTITUTIVELY ACTIVE MUTANTS OF GCAP1 CAUSE RETINAL DISEASE
------------------------------------------------------------

Various point mutations in the EF-hand motifs of GCAP1 that weaken Ca^2+^ binding (but do not affect Mg^2+^ binding) cause GCAP1 to constitutively activate RetGC in rods and cones, which is genetically linked to various retinal diseases ([@B62]). These mutations in the EF-hand motifs \[Y99C ([@B32]; [@B99]) and E155G ([@B136], [@B135])\] weaken the Ca^2+^ binding affinity beyond the photoreceptor Ca^2+^ concentration and cause the Ca^2+^-free/Mg^2+^-bound GCAP1 activator state to persist even at high Ca^2+^ levels in dark-adapted rods, which causes persistent activation of RetGC ([@B117]; [@B93]). The GCAP mutants that constitutively activate RetGC then cause elevated cGMP levels in photoreceptor cells that promotes apoptosis and disease ([@B93], [@B95]; [@B137]).

Mutagenesis studies of the individual EF-hands in GCAP1 have revealed that Ca^2+^-binding to EF4 is critical for controlling Ca^2+^-dependent activation of RetGC ([@B102]). Mutants of GCAP1 that weaken or abolish Ca^2+^ binding to EF4 but retain Ca^2+^ binding at EF2 and EF3 \[D144N/D148G ([@B102] and E155G [@B136], [@B135])\] are constitutively active even in the presence of high Ca^2+^ levels in dark-adapted photoreceptors. Furthermore, these mutants that disable Ca^2+^ binding to EF4 (but not EF2 and EF3) are unable to inhibit RetGC at high Ca^2+^ levels in the dark ([@B102]). In summary, GCAP1 can activate RetGC even if Ca^2+^ is bound to EF2 and EF3 (but not bound to EF4). Also, Ca^2+^ binding to EF4 is essential for having Ca^2+^-induced inhibition of RetGC. Therefore, Ca^2+^ binding to EF4 is critical for controlling whether GCAP1 can activate or inhibit RetGC.

GCAPs DO NOT POSSESS A Ca^2+^-MYRISTOYL SWITCH
----------------------------------------------

Ca^2+^ binding to GCAP1 and GCAP2 does not cause ejection of the covalently attached myristoyl group ([@B55]; [@B77], [@B78]) and Ca^2+^ binding to GCAPs do not promote their membrane targeting ([@B94]; [@B58]). This is in stark contrast to the Ca^2+^-induced exposure of the N-terminal myristoyl group \[termed Ca^2+^-myristoyl switch ([@B140]; [@B33])\] that promotes membrane targeting of recoverin ([@B140]; [@B33]; [@B130]), neurocalcin ([@B74]), hippocalcin ([@B90]), VILIPs ([@B119], [@B118]), and NCS-1 ([@B51]). Instead, the covalently attached myristoyl group of GCAP1 remains sequestered inside the protein hydrophobic core in both Ca^2+^-free and Ca^2+^-bound forms of GCAP1 ([@B77], [@B78]). NMR studies on the myristate attached to recoverin ([@B7], [@B4]; [@B56]), VILIP1 ([@B76]), and NCS-1 ([@B79]) reveal that the covalently attached myristoyl group is buried inside these proteins only in the Ca^2+^-free state. Ca^2+^-binding causes protein conformational changes that lead to exposure of the fatty acyl chain in recoverin ([@B4]), VILIP1 ([@B76]), and NCS-1 ([@B79]). By stark contrast, NMR studies on GCAP1 indicate that the covalently attached myristoyl group is buried inside both Ca^2+^-free and Ca^2+^-bound GCAP1 ([@B77], [@B78]). Further evidence that GCAP1 lacks a Ca^2+^-myristoyl switch comes from SPR studies that show myristoylation of GCAP1 has little effect on membrane binding ([@B58]). Finally, the recent atomic level structures of GCAP1 directly demonstrated that the myristoyl group is buried inside the protein in a similar environment in both the Ca^2+^-free activator ([@B78]) and Ca^2+^-bound inhibitor states ([@B120]).

Solid-state NMR and other spectroscopic studies on GCAP2 have suggested that Ca^2+^-free GCAP2 might be targeted to cell membranes by a reversed Ca^2+^-myristoyl switch ([@B127], [@B128]). The covalently attached fatty acyl group has been suggested to become exposed in Ca^2+^-free GCAP2 in the presence of lipid bilayer membranes ([@B128]), in contrast to having the myristoyl group sequestered inside Ca^2+^-bound GCAP2 ([@B114]). However, other studies on GCAP2 indicate that the myristoyl group remains sequestered inside the protein environment in both Ca^2+^-free and Ca^2+^-bound GCAP2 ([@B55]). Also, unmyristoylated GCAP2 activates RetGC with nearly the same potency as that of myristoylated GCAP2, and myristoylation of GCAP2 is not essential for its targeting to the membrane-bound cyclase ([@B94]; [@B58]).

Ca^2+^-INDUCED PROTEIN CONFORMATIONAL CHANGES IN GCAPs
------------------------------------------------------

Atomic level structures are known for Ca^2+^-bound forms of GCAP1 ([@B120]) and GCAP2 ([@B2]). The four EF-hands in GCAP1 (**Figures [1](#F1){ref-type="fig"}** and **[3](#F3){ref-type="fig"}**) are grouped into two globular domains: N-domain includes EF1 and EF2 (residues 18--83) and C-domain contains EF3 and EF4 (residues 88--161). Ca^2+^ is bound to GCAP1 at EF2, EF3 and EF4, and the structure of each Ca^2+^-bound EF-hand in GCAP1 (**Figure [3B](#F3){ref-type="fig"}**) adopts the familiar open conformation of EF-hands as seen in calmodulin and other Ca^2+^-bound EF-hand proteins ([@B60]). Indeed, the interhelical angles for each Ca^2+^-bound EF-hand in GCAP1 are similar to those of recoverin ([@B4]) and NCS-1 ([@B16]). Although the internal structure of each EF-hand in GCAP1 is similar to that of recoverin, the overall three-dimensional packing arrangement and spatial organization of the four EF-hands is very different for GCAP1 vs. recoverin. Indeed, the overall root-mean-squared deviation of main chain atoms is 3.4 Å when comparing the structures of GCAP1 and recoverin (**Figure [2](#F2){ref-type="fig"}**). A unique structural feature of GCAP1 is that the N-terminal α-helix (residues 5--15) upstream of EF1 and C-terminal helix (residues 175--183) downstream of EF4 are held closely together by their mutual interaction with the N-terminal myristoyl group (**Figure [2F](#F2){ref-type="fig"}**). Thus, the covalently attached myristoyl group in GCAP1 is sequestered within a unique environment inside the Ca^2+^-bound protein, which is quite different from that of recoverin as described above in **Figure [2](#F2){ref-type="fig"}**. The myristoyl group attached to GCAP1 makes contacts with N-terminal residues (V9, L12, and F42) and the C-terminal helix (L174, V178 and I181; **Figure [2F](#F2){ref-type="fig"}**). In essence, the myristoyl group serves to bridge both the N-terminal and C-terminal ends of the protein, which explains how Ca^2+^-induced conformational changes in the C-terminal domain (particularly in EF4) might be transmitted to a possible target binding site in EF1. A Ca^2+^-myristoyl tug mechanism ([@B104]) has been proposed to explain how Ca^2+^-induced conformational changes in EF4 serve to "tug" on the adjacent C-terminal helix that connects structurally to the myristoyl group and EF1. This tug mechanism helps explain how Ca^2+^-induced structural changes in EF4 might be relayed to the cyclase binding region in EF1 ([@B78]). The Ca^2+^-induced structural changes involving the C-terminal helix might also be related to Ca^2+^-dependent phosphorylation of S201 in GCAP2 ([@B103]).

![**Structures of activator (A)** vs. inhibitor forms **(B)** of GCAP1 adapted from and originally published by [@B78].](fnmol-07-00019-g003){#F3}

The atomic level structure of Ca^2+^-free/Mg^2+^-bound activator form of GCAP1 or GCAP2 is currently not known. The main difficulty is that Ca^2+^-free/Mg^2+^-bound GCAP proteins form dimers and higher order protein oligomers that causes considerable sample heterogeneity at high protein concentrations needed for NMR or to make crystals for X-ray crystallography ([@B2]; [@B77], [@B78]). Ca^2+^-dependent dimerization of GCAP2 has been suggested to be important for activating the cyclase ([@B92]; [@B42]). Protein dimerization was also reported for GCAP1, and a GCAP1 mutant (V77E) that prevents protein dimerization also abolishes its ability to activate RetGC, suggesting that dimerization of Ca^2+^-free/Mg^2+^-bound activator state might be important for activating RetGC ([@B78]). However, protein dimerization of GCAP1 is not Ca^2+^ dependent and only occurs at relatively high protein concentrations above 100 μ M ([@B78]). Future studies are needed to investigate whether GCAPs might form a functional dimer upon binding to the dimeric RetGC to form a 2:2 complex ([@B111]; [@B106]), and whether the dimeric quaternary structure may play a regulatory role.

A GCAP1 mutant, D144N/D148G called EF4mut, ([@B78]) that binds Ca2+ at EF2 and EF3 (and does not bind Ca^2+^ at EF4) can activate RetGC at high Ca^2+^ concentrations ([@B102]). Therefore, EF4mut (with Ca^2+^ bound at EF2 and EF3) serves as a model of the Ca^2+^-free/Mg^2+^-bound activator state. The EF4mut protein is more soluble and stable than Ca^2+^-free/Mg^2+^-bound wild type, and EF4mut exhibits NMR spectra with much higher resolution and sensitivity compared to that of Ca^2+^-free/Mg^2+^-bound wild type ([@B77], [@B78]). NMR structural studies on EF4mut provide some insights for a structural model of the GCAP1 activator state (**Figure [3A](#F3){ref-type="fig"}**). The overall structure of EF4mut is similar to the crystal structure of Ca^2+^-bound GCAP1 (root mean squared deviation of main chain atoms is 1.3 Å when comparing the two structures). However, residues at the domain interface (between EF2 and EF3) are structured somewhat differently in EF4mut compared to the crystal structure of Ca^2+^-bound GCAP1. Many of the GCAP1 residues at the domain interface have quite broad NMR resonances, suggesting that these residues are conformationally dynamic ([@B78]). The corresponding residues in recoverin (**Figure [1](#F1){ref-type="fig"}**) also exhibited broad NMR resonances and ^15^N NMR relaxation dispersion studies reveal that these domain interface residues exhibit millisecond exchange kinetics ([@B139]). Ca^2+^-induced rearrangement of residues at the domain interface in recoverin gives rise to a 45° swiveling of the two domains ([@B4]). A structural comparison between EF4mut and Ca^2+^-bound GCAP1 suggests a related but much smaller Ca^2+^-induced structural change at the domain interface in GCAP1 (**Figure [3](#F3){ref-type="fig"}**). The most noteworthy Ca^2+^-induced structural difference in GCAP1 can be seen in the entering helix of EF3 that unravels a half turn in EF4mut, which causes a repositioning of the W94 side-chain at the domain interface. A Ca^2+^-induced change in the structural environment around W94 is consistent with previous tryptophan fluorescence and electron paramagnetic resonance studies of GCAP1 ([@B116]; [@B101], [@B102]). We suggest that Ca^2+^-induced rearrangement of residues at the domain interface (V77, A78, L82, K85, and W94) plays a role in modulating Ca^2+^-dependent contacts with RetGC1.

ACTIVATION MECHANISM FOR RetGC BY GCAPs
---------------------------------------

The structural information for the GCAPs above provides insights into the activation mechanism of RetGC (**Figure [4](#F4){ref-type="fig"}**). GCAP1 residues in EF1 ([@B73]; [@B91],[@B92]; [@B42]) and at the domain interface ([@B73]; [@B78]; [@B105]) are suggested to make direct contact with RetGC (see labeled residues in **Figure [4](#F4){ref-type="fig"}**). In our model (**Figure [4](#F4){ref-type="fig"}**), Ca^2+^-induced conformational changes in EF4 ([@B78]) are transmitted to the cyclase binding site (see labeled residues in EF1, EF2, and EF3, **Figure [4](#F4){ref-type="fig"}**) by a Ca^2+^-myristoyl tug mechanism as described by ([@B104]). In the GCAP1 activator state under physiological conditions (**Figure [4](#F4){ref-type="fig"}**, left panel), EF2 and EF3 are bound to Mg^2+^ (blue circles in **Figure [4](#F4){ref-type="fig"}**) with EF1 and EF4 unoccupied. The Ca^2+^-free state of EF4 forms a loose and dynamic structure ([@B78]), which allows the adjacent C-terminal helix to reach all the way to the N-terminal myristoyl group (magenta in **Figure [4](#F4){ref-type="fig"}**) and thus indirectly form hydrophobic contacts with residues in EF1 and EF2. In essence, the myristoyl group forms a bridge between Ca^2+^-induced conformational changes in the C-terminal domain and the cyclase binding site in the N-terminal domain. In the GCAP1 activator state, residues in the cyclase binding site \[see **Figure [4](#F4){ref-type="fig"}**, labeled residues in EF1, EF2 and EF3 ([@B105])\] are spatially close together and form particular contacts with RetGC that require close proximity between W94 and V77 (see arrow in **Figure [4](#F4){ref-type="fig"}**). In the Ca^2+^-bound GCAP1 inhibitor state (**Figure [4](#F4){ref-type="fig"}**, right panel), Ca^2+^ is bound to EF2, EF3, and EF4 (orange circles in **Figure [4](#F4){ref-type="fig"}**). Ca^2+^-binding to EF4 causes local conformational changes that in turn "tug" on the C-terminal helix which causes a slight reorientation of the N-terminal domain (EF1 and EF2) with respect to the C-terminal domain (EF3 and EF4). This domain swiveling causes key residues in EF3 at the domain interface (K85, W94, and K97) to move farther away from cyclase binding site residues in EF2 \[F73, V77, and A78 ([@B105])\], which disrupts key contacts to RetGC that we suggest may be important for regulating cyclase activation.

![**Schematic diagram of retinal guanylyl cyclase activation by GCAP1.** RetGC is shown in gray. The four EF-hands in GCAP1 are colored coded as defined in **Figure [1](#F1){ref-type="fig"}**, bound Mg^2+^ are depicted by blue circles, bound Ca^2+^ are orange circles, the C-terminal helix is white, and N-terminal myristoyl group is magenta. The labeled GCAP1 residues (K23, M26, G32, F73, V77, A78, and W94) have been implicated in the RetGC binding site ([@B78]; [@B105]). The binding of Ca^2+^ at EF4 causes conformational changes that are transmitted to the RetGC binding site by a Ca^2+^-myristoyl tug mechanism (see arrows) modified from [@B104].](fnmol-07-00019-g004){#F4}

CONCLUSION
==========

N-terminal myristoylation serves to remodel the structure of NCS proteins as seen for recoverin, GCAP1 and NCS-1. Each NCS protein folds differently around the attached myristoyl group, which causes each NCS protein to adopt a unique structure. Most NCS proteins possess a functional Ca^2+^-myristoyl switch that promotes their Ca^2+^-induced membrane targeting. By contrast, GCAP1 contains a sequestered myristoyl group in both its Ca^2+^-free and Ca^2+^-bound states and undergoes rather small Ca^2+^-induced protein conformational changes. Ca^2+^ binding to the fourth EF-hand in GCAP1 triggers conformational changes in the N-terminal domain via a Ca^2+^-myristoyl tug mechanism that controls the exposure of residues in EF1 and EF2 that we propose may serve as a target binding site for guanylyl cyclase.
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